Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma Inc (ALPMF)
OTHER OTC:ALPMF
Holding ALPMF?
Track your performance easily
Earnings Data
Report Date
Feb 04, 2025TBA Not Confirmed
Period Ending
2024 (Q3)Consensus EPS Forecast
0.14Last Year’s EPS
0.07Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2018
|% Change Since: -19.74%
|Next Earnings Date:Jul 27, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance in oncology products and positive developments in clinical trials, particularly with PADCEV and IZERVAY. However, these were offset by significant declines in core operating profit and operating profit due to acquisition-related expenses and underperformance of VEOZAH.Company Guidance
During the Astellas Pharma Inc.'s FY 2023 Second Quarter earnings call, the company provided guidance on several key financial metrics and strategic initiatives. Revenue for the quarter increased to JPY 767.1 billion, marking a 0.6% year-on-year rise, with a 50.5% progress towards the full-year forecast. However, core operating profit declined by 24.5% to JPY 109.8 billion, impacted by the LEXISCAN generic and the acquisition of Iveric Bio, leading to a downward revision of the full-year operating profit forecast. Notably, oncology products such as XTANDI, PADCEV, and XOSPATA exceeded expectations, prompting an upward revision of their combined forecast by approximately JPY 18 billion. Despite the underperformance of VEOZAH, which was attributed to lower-than-expected out-of-pocket usage and procedural hurdles, its long-term potential remains optimistic. The initial uptake of IZERVAY was aligned with expectations, contributing JPY 1.2 billion in sales since its September launch. Looking ahead, Astellas expects significant growth from strategic products like VEOZAH, PADCEV, and IZERVAY, although achieving a core operating profit margin of 30% by FY 2025 may be challenging. The call also highlighted ongoing efforts in cost optimization and resource allocation to drive sustainable growth.Strong Performance in Oncology Products
XTANDI, PADCEV, and XOSPATA combined exceeded expectations. PADCEV global sales increased by 57% year-on-year, and XOSPATA sales increased by 12% year-on-year.
Positive Developments in Clinical Trials
PADCEV EV-302 study results were extremely favorable, exceeding expectations, leading to a planned earlier submission for additional indications.
IZERVAY Initial Uptake on Track
IZERVAY launched in September with initial sales of JPY 1.2 billion, aligning with expectations.
---
ALPMF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALPMF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $11.40 | $12.00 | +5.26% |
| Aug 01, 2024 | $11.60 | $11.40 | -1.72% |
| Apr 25, 2024 | $9.44 | $9.84 | +4.24% |
| Feb 05, 2024 | $11.58 | $11.10 | -4.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Astellas Pharma Inc (ALPMF) report earnings?
Astellas Pharma Inc (ALPMF) is schdueled to report earning on Feb 04, 2025, TBA Not Confirmed.
What is Astellas Pharma Inc (ALPMF) earnings time?
Astellas Pharma Inc (ALPMF) earnings time is at Feb 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALPMF EPS forecast?
ALPMF EPS forecast for the fiscal quarter 2024 (Q3) is 0.14.
---